Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial
- PMID: 12221168
- DOI: 10.1212/wnl.59.5.744
Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial
Abstract
Depression is a suspected side effect of treatment with interferon beta1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon beta1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon beta1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon beta1a.
Comment in
-
Multiple sclerosis, depression, and the risk of suicide.Neurology. 2002 Sep 10;59(5):662-3. doi: 10.1212/wnl.59.5.662. Neurology. 2002. PMID: 12221154 No abstract available.
-
Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicide.Neurology. 2002 Sep 10;59(5):E6-7. doi: 10.1212/wnl.59.5.e6. Neurology. 2002. PMID: 12221194 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources